Health-Related Quality of Life in Patients with Chronic Hepatitis B: A Meta-Analysis of Observational Studies
-
Saniya Saussakova
,
Gaukhar Dauletova
,
Zhandulla Nakipov
,
Gulzat Sarsenbayeva
,
Samal Duisekova
,
Zhanat Sadibekova
,
Karlygash Raissova
,
Assiya Turgambayeva
Abstract
Background: Chronic hepatitis B virus (CHB) infection is one of the most common liver infections worldwide. Approximately 240 million patients are diagnosed with CHB. The objective of this meta-analysis was to identify the effect of CHB on the affected patients’ health-related quality of life and compare with the control group.
Methods: A comprehensive search was conducted through PubMed, Medline, ProQuest, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, and Web of Science databases up to Jul 2022.
Results: Five primary observational studies using SF-36 and WHOQOL surveys with 1135 participants (646 with CHB and 489 healthy individuals) included in the meta-analysis. We evaluated the scores of physical and mental component summaries. HRQoL was comparable in both groups. The disease's impact appears to slightly affect the mental component summary than the physical component summary.
Conclusion: The HRQoL in CHB patients is mainly reflected in the impairment of the mental aspect. It is vital to focus on optimally managing care, family and social support, stress management.
1. Sarin SK, Kumar M, Lau GK et al (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int, 10:1–98.
2. Lu JB, Cai SH, Pan YH et al (2018). Altered epidermal fatty acid-binding protein ex-pression in hepatocellular carcinoma pre-dicts unfavorable outcomes. Cancer Manag Res, 10:6275–6284.
3. Xiao YB, Cai SH, Liu LL et al (2018). De-creased expression of peroxisome prolif-erator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. Cancer Manag Res,10:1781–1789.
4. Lok AS, McMahon BJ (2009). Chronic hep-atitis B: update 2009. Hepatology, 50:661–662.
5. Cai S, Cao J, Yu T et al (2017). Effectiveness of entecavir or telbivudine therapy in pa-tients with chronic hepatitis B virus infec-tion pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore), 96:e7021.
6. Ott JJ, Stevens GA, Groeger J et al (2012). Global epidemiology of hepatitis B virus infection: new estimates of age‐specific HBsAg seroprevalence and endemicity. Vaccine, 30:2212‐2219.
7. World Health Organization (2016). Global health sector strategy on viral hepatitis 2016-2021. Global Hepatitis Programme De-partment of HIV/AIDS, 56.
8. Wang T (2009). Model of life expectancy of chronic hepatitis b carriers in an endemic region. J. Epidemiol, 19,311–318.
9. Dakhil N, Junaidi O, Befeler AS (2009). Chronic viral hepatitis. Mo Med, 06(5):361-5.
10. Ryder SD, Beckingham IJ (2001). ABC of diseases of liver, pancreas, and biliary sys-tem: Acute hepatitis. BMJ, 322(7279):151-3.
11. Ansari S, Siddiqui M, Malhotra S et al (2019). Unani Formulation Improved Quality of Life in Indian Patients of Chronic Hepa-titis B. Journal of Young Pharma-cists,11(4):353-360.
12. Lok AS, McMahon BJ (2007). Chronic hep-atitis B. Hepatology, 45(2):507-39.
13. Fayers P, Machin D (2013). Quality of Life: the assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. John Wiley & Sons. Chichester.
14. Staquet M, Berzon R, Osoba D et al (1996). Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res, 5(5):496–502.
15. World Health Organization (2015). World report on ageing and health. Health Ser-vices for the Aged, 260.
16. Schipper H, Clinch JJ, Olweny CL (1996). Quality of life studies: Definitions and conceptual issues. 2nd ed. Lippincott-Raven. New York.
17. Ong SC, Mak B, Myat OA et al (2008). Health-related quality of life in chronic hepatitis B patients. Hepatology, 47: 1108–1117.
18. Ha Y, Hwang S, Chon Y et al (2019). Valida-tion of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study. J Clin Med, 8(5):656.
19. Lam ET, Lam CL, Lai CL et al (2009). Health-related quality of life of Southern Chinese with chronic hepatitis B infec-tion. Health Qual Life Outcomes, 7:52.
20. Chao J, Song L, Zhang H et al (2013). Ef-fects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China. BMC Health Serv Res, 13:386.
21. Chen MC, Hung HC, Chang HJ et al (2017). Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Pa-tients. BMC Health Serv Res,17(1):148.
22. Karacaer Z, Cakir B, Erdem H et al (2016). Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey. Health Qual Life Outcomes, 14(1): 153.
23. Lam ET, Lam CL, Lai CL et al (2009). Psy-chometrics of the chronic liver disease questionnaire for Southern Chinese pa-tients with chronic hepatitis B virus infec-tion. World J Gastroenterol, 15(26): 3288–3297.
24. Tan NC, Cheah SL, Teo EK et al (2008). Patients with chronic hepatitis B infec-tion: What is their quality of life? Singapore Med J, 49(9): 682–687.
25. Zhou K, Zhang M, Wu Q et al (2013). Reli-ability, validity and sensitivity of the Chi-nese (simple) short form 36 health survey version 2 (SF-36v2) in patients with chronic hepatitis B. J Viral Hepat, 20(4): e47-55.
26. Patanwala N, Elliot C, Frith J et al (2010). Functional capacity is significantly im-paired in primary biliary cirrhosis and re-lated to orthostatic symptoms. Gut, 59:A19–20.
27. Newton JL, Pairman J, Sutcliffe K et al (2008). A predictive model for fatigue and its aetiological associations in primary bil-iary cirrhosis. Clin Gastroenterol Hepatol, 6:228–3.
28. Sharif F, Mohebbi S, Tabatabaee HR et al (2005). Effects of psycho-educational in-tervention on health-related quality of life (QOL) of patients with chronic liver dis-ease referring to Shiraz University of Medical Sciences. Health Qual Life Out-comes, 3: 81-86.
29. Moher D, Liberati A, Tetzlaff J et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6:e1000097.
30. RAND Corporation (2019). 36-Item Short Form Survey (SF-36). www.rand.org.
31. Ware JE, Snow KK, Kosinski M et al (1993). SF-36 Health Survey Manual and Interpreta-tion Guide. New England Medical Center. Boston.
32. The WHOQOL Group Development of the World Health Organization WHOQOL-BREF quality of life assess-ment (1998). Psychol Med, 28(3):551–558.
33. Von Elm E, Altman DG, Egger M et al (2007). The Strengthening the Reporting of Observational Studies in Epidemiolo-gy (STROBE) statement: guidelines for reporting observational studies. Prev Med, 85(11): 867–872.
34. Wells GA, Tugwell P, O’Connell D et al (2015). The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Clin Epidemil,2:4-10.
35. Luchini C, Stubbs B, Solmi M et al (2017). Assessing the quality of studies in meta-analysis: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal,5:1–48.
36. Higgins JPT, Green S (2008). Cochrane hand-book for systematic reviews. Hoboken. Chich-ester.
37. Cohen J (1992). Statistical power analysis. Curr Dir Psychol Sci,1:98–101.
38. Higgins JP, Thompson SG (2002). Quanti-fying heterogeneity in a meta-analysis. Stat Med, 21:1539–1558.
39. Higgins JPT, Thompson SG, Deeks JJ et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327:557–560.
40. Xiao J, Chen P, Li XB et al (2012). Survey of patients with chronic hepatitis B to identi-fy factors that influence quality of life. Zhonghua Gan Zang Bing Za Zhi, 20(9):649-53.
41. Altindag A, Cadirci D, Sirmatel F (2009). Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers. Neurosci-ences, 14(1):56-9.
42. Chen P, Zhang F, Shen Y et al (2021). Health-Related Quality of Life and Its In-fluencing Factors in Patients with Hepati-tis B: A Cross-Sectional Assessment in Southeastern China. Can J Gastroenterol Hepatol, 7:9937591.
43. Borenstein M, Hedges LV, Higgins JPT et al (2010). A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods, 1(2):97–111.
44. World Health Organization (2015). Guide-lines for the prevention, care and treat-ment of persons with chronic hepatitis B infection. World Health Organization, 1-166.
45. World Health Organization (2016). Combat-ing hepatitis B and C to reach elimination by 2030. World Health Organization, 1–16.
46. Mahassadi AK, Team Machekam O, Attia AK (2020). The Impact of Virologic Pa-rameters and Liver Fibrosis on Health-Related Quality of Life in Black African Patients with Chronic Hepatitis B: Results from a High Endemic Area. Clin Exp Gastroentero,13:407-418.
47. Oral B, Gun E, Cetinkaya F (2020). Evalua-tion of Health-Related Life Quality of Pa-tients with Chronic Hepatitis Admitted to a Medical Faculty Hospital. Viral Hepatitis Journal, 26(3):151-157.
48. Bondini S, Kallman J, Dan A et al (2007). Health-related quality of life in patients with chronic hepatitis B. Liver Int, 27(8):1119–1125.
49. Daida YG, Boscarino JA, Moorman AC et al (2020). Mental and physical health sta-tus among chronic hepatitis B patients. Qual Life Res, 29(6):1567-1577.
50. Kim SJ, Han KT, Lee SY et al (2015). Quali-ty of life correlation with socioeconomic status in Korean hepatitis-B patients: a cross sectional study. Health Qual Life Out-comes,13:55.
51. Zhang M, Li Y, Fan Z et al (2021). As-sessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. BMJ Open, 11(9):e047475.
52. Li G, Wang G, Hsu FC et al (2020). Effects of Depression, Anxiety, Stigma, and Dis-closure on Health-Related Quality of Life among Chronic Hepatitis B Patients in Dalian, China. Am J Trop Med Hyg, 102(5):988-994.
53. Vu TTM, Le TV, Dang AK et al (2019). So-cioeconomic Vulnerability to Depressive Symptoms in Patients with Chronic Hep-atitis B. Int J Environ Res Public Health, 16(2):255.
54. Evon DM, Lin HS, Khalili M et al (2020). Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther, 51(4):457-468.
55. Woo G, Tomlinson G, Yim C et al (2012). Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenter-ol, 26(7):445–451.
2. Lu JB, Cai SH, Pan YH et al (2018). Altered epidermal fatty acid-binding protein ex-pression in hepatocellular carcinoma pre-dicts unfavorable outcomes. Cancer Manag Res, 10:6275–6284.
3. Xiao YB, Cai SH, Liu LL et al (2018). De-creased expression of peroxisome prolif-erator-activated receptor alpha indicates unfavorable outcomes in hepatocellular carcinoma. Cancer Manag Res,10:1781–1789.
4. Lok AS, McMahon BJ (2009). Chronic hep-atitis B: update 2009. Hepatology, 50:661–662.
5. Cai S, Cao J, Yu T et al (2017). Effectiveness of entecavir or telbivudine therapy in pa-tients with chronic hepatitis B virus infec-tion pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore), 96:e7021.
6. Ott JJ, Stevens GA, Groeger J et al (2012). Global epidemiology of hepatitis B virus infection: new estimates of age‐specific HBsAg seroprevalence and endemicity. Vaccine, 30:2212‐2219.
7. World Health Organization (2016). Global health sector strategy on viral hepatitis 2016-2021. Global Hepatitis Programme De-partment of HIV/AIDS, 56.
8. Wang T (2009). Model of life expectancy of chronic hepatitis b carriers in an endemic region. J. Epidemiol, 19,311–318.
9. Dakhil N, Junaidi O, Befeler AS (2009). Chronic viral hepatitis. Mo Med, 06(5):361-5.
10. Ryder SD, Beckingham IJ (2001). ABC of diseases of liver, pancreas, and biliary sys-tem: Acute hepatitis. BMJ, 322(7279):151-3.
11. Ansari S, Siddiqui M, Malhotra S et al (2019). Unani Formulation Improved Quality of Life in Indian Patients of Chronic Hepa-titis B. Journal of Young Pharma-cists,11(4):353-360.
12. Lok AS, McMahon BJ (2007). Chronic hep-atitis B. Hepatology, 45(2):507-39.
13. Fayers P, Machin D (2013). Quality of Life: the assessment, analysis and interpretation of patient-reported outcomes. 2nd ed. John Wiley & Sons. Chichester.
14. Staquet M, Berzon R, Osoba D et al (1996). Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res, 5(5):496–502.
15. World Health Organization (2015). World report on ageing and health. Health Ser-vices for the Aged, 260.
16. Schipper H, Clinch JJ, Olweny CL (1996). Quality of life studies: Definitions and conceptual issues. 2nd ed. Lippincott-Raven. New York.
17. Ong SC, Mak B, Myat OA et al (2008). Health-related quality of life in chronic hepatitis B patients. Hepatology, 47: 1108–1117.
18. Ha Y, Hwang S, Chon Y et al (2019). Valida-tion of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study. J Clin Med, 8(5):656.
19. Lam ET, Lam CL, Lai CL et al (2009). Health-related quality of life of Southern Chinese with chronic hepatitis B infec-tion. Health Qual Life Outcomes, 7:52.
20. Chao J, Song L, Zhang H et al (2013). Ef-fects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China. BMC Health Serv Res, 13:386.
21. Chen MC, Hung HC, Chang HJ et al (2017). Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Pa-tients. BMC Health Serv Res,17(1):148.
22. Karacaer Z, Cakir B, Erdem H et al (2016). Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey. Health Qual Life Outcomes, 14(1): 153.
23. Lam ET, Lam CL, Lai CL et al (2009). Psy-chometrics of the chronic liver disease questionnaire for Southern Chinese pa-tients with chronic hepatitis B virus infec-tion. World J Gastroenterol, 15(26): 3288–3297.
24. Tan NC, Cheah SL, Teo EK et al (2008). Patients with chronic hepatitis B infec-tion: What is their quality of life? Singapore Med J, 49(9): 682–687.
25. Zhou K, Zhang M, Wu Q et al (2013). Reli-ability, validity and sensitivity of the Chi-nese (simple) short form 36 health survey version 2 (SF-36v2) in patients with chronic hepatitis B. J Viral Hepat, 20(4): e47-55.
26. Patanwala N, Elliot C, Frith J et al (2010). Functional capacity is significantly im-paired in primary biliary cirrhosis and re-lated to orthostatic symptoms. Gut, 59:A19–20.
27. Newton JL, Pairman J, Sutcliffe K et al (2008). A predictive model for fatigue and its aetiological associations in primary bil-iary cirrhosis. Clin Gastroenterol Hepatol, 6:228–3.
28. Sharif F, Mohebbi S, Tabatabaee HR et al (2005). Effects of psycho-educational in-tervention on health-related quality of life (QOL) of patients with chronic liver dis-ease referring to Shiraz University of Medical Sciences. Health Qual Life Out-comes, 3: 81-86.
29. Moher D, Liberati A, Tetzlaff J et al (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6:e1000097.
30. RAND Corporation (2019). 36-Item Short Form Survey (SF-36). www.rand.org.
31. Ware JE, Snow KK, Kosinski M et al (1993). SF-36 Health Survey Manual and Interpreta-tion Guide. New England Medical Center. Boston.
32. The WHOQOL Group Development of the World Health Organization WHOQOL-BREF quality of life assess-ment (1998). Psychol Med, 28(3):551–558.
33. Von Elm E, Altman DG, Egger M et al (2007). The Strengthening the Reporting of Observational Studies in Epidemiolo-gy (STROBE) statement: guidelines for reporting observational studies. Prev Med, 85(11): 867–872.
34. Wells GA, Tugwell P, O’Connell D et al (2015). The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. Clin Epidemil,2:4-10.
35. Luchini C, Stubbs B, Solmi M et al (2017). Assessing the quality of studies in meta-analysis: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal,5:1–48.
36. Higgins JPT, Green S (2008). Cochrane hand-book for systematic reviews. Hoboken. Chich-ester.
37. Cohen J (1992). Statistical power analysis. Curr Dir Psychol Sci,1:98–101.
38. Higgins JP, Thompson SG (2002). Quanti-fying heterogeneity in a meta-analysis. Stat Med, 21:1539–1558.
39. Higgins JPT, Thompson SG, Deeks JJ et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327:557–560.
40. Xiao J, Chen P, Li XB et al (2012). Survey of patients with chronic hepatitis B to identi-fy factors that influence quality of life. Zhonghua Gan Zang Bing Za Zhi, 20(9):649-53.
41. Altindag A, Cadirci D, Sirmatel F (2009). Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers. Neurosci-ences, 14(1):56-9.
42. Chen P, Zhang F, Shen Y et al (2021). Health-Related Quality of Life and Its In-fluencing Factors in Patients with Hepati-tis B: A Cross-Sectional Assessment in Southeastern China. Can J Gastroenterol Hepatol, 7:9937591.
43. Borenstein M, Hedges LV, Higgins JPT et al (2010). A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods, 1(2):97–111.
44. World Health Organization (2015). Guide-lines for the prevention, care and treat-ment of persons with chronic hepatitis B infection. World Health Organization, 1-166.
45. World Health Organization (2016). Combat-ing hepatitis B and C to reach elimination by 2030. World Health Organization, 1–16.
46. Mahassadi AK, Team Machekam O, Attia AK (2020). The Impact of Virologic Pa-rameters and Liver Fibrosis on Health-Related Quality of Life in Black African Patients with Chronic Hepatitis B: Results from a High Endemic Area. Clin Exp Gastroentero,13:407-418.
47. Oral B, Gun E, Cetinkaya F (2020). Evalua-tion of Health-Related Life Quality of Pa-tients with Chronic Hepatitis Admitted to a Medical Faculty Hospital. Viral Hepatitis Journal, 26(3):151-157.
48. Bondini S, Kallman J, Dan A et al (2007). Health-related quality of life in patients with chronic hepatitis B. Liver Int, 27(8):1119–1125.
49. Daida YG, Boscarino JA, Moorman AC et al (2020). Mental and physical health sta-tus among chronic hepatitis B patients. Qual Life Res, 29(6):1567-1577.
50. Kim SJ, Han KT, Lee SY et al (2015). Quali-ty of life correlation with socioeconomic status in Korean hepatitis-B patients: a cross sectional study. Health Qual Life Out-comes,13:55.
51. Zhang M, Li Y, Fan Z et al (2021). As-sessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study. BMJ Open, 11(9):e047475.
52. Li G, Wang G, Hsu FC et al (2020). Effects of Depression, Anxiety, Stigma, and Dis-closure on Health-Related Quality of Life among Chronic Hepatitis B Patients in Dalian, China. Am J Trop Med Hyg, 102(5):988-994.
53. Vu TTM, Le TV, Dang AK et al (2019). So-cioeconomic Vulnerability to Depressive Symptoms in Patients with Chronic Hep-atitis B. Int J Environ Res Public Health, 16(2):255.
54. Evon DM, Lin HS, Khalili M et al (2020). Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther, 51(4):457-468.
55. Woo G, Tomlinson G, Yim C et al (2012). Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenter-ol, 26(7):445–451.
| Files | ||
| Issue | Vol 52 No 3 (2023) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i3.12129 | |
| Keywords | ||
| Quality of life Health-related quality of life Chronic hepatitis B patients Meta-analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Saussakova S, Dauletova G, Nakipov Z, Sarsenbayeva G, Duisekova S, Sadibekova Z, Raissova K, Turgambayeva A. Health-Related Quality of Life in Patients with Chronic Hepatitis B: A Meta-Analysis of Observational Studies. Iran J Public Health. 2023;52(3):453-462.
